6th International Virtual Congress (IVC-2019) And Workshop.  International E-publication: Publish Projects, Dissertation, Theses, Books, Souvenir, Conference Proceeding with ISBN.  International E-Bulletin: Information/News regarding: Academics and Research

Dengue infection and molecular mechanism of spreading

Author Affiliations

  • 1Institute of Pesticide Formulation Technology (IPFT), Sec-20, UdyogVihar, Gurugram-122016, Haryana, India
  • 2Institute of Pesticide Formulation Technology (IPFT), Sec-20, UdyogVihar, Gurugram-122016, Haryana, India
  • 3Institute of Pesticide Formulation Technology (IPFT), Sec-20, UdyogVihar, Gurugram-122016, Haryana, India

Int. Res. J. Medical Sci., Volume 7, Issue (2), Pages 1-5, May,28 (2019)

Abstract

This article highlights a brief overview about the Dengue Fever (DF), its distribution around the world, symptoms and cuse of spreading mechanism. Also, using of bio-pesticides have been discussed with the beneficial effects to control the disease. Dengue fever (DF) is a well known and serious disease, spreaded by Aedesmosquitoes. The virus which is responsible for the transmission of the disease made its host to the Aedesmosquito. The four serotypes of the dengue viruses are responsible for the infection, which results in the acute fever, skin rashes, heamorage and sometimes even shock to the patient. We are also highlighting the molecular ineteractions mechanism of virus and the host cell with emphasizing the receptor molecuels of the host cell surface, which is considered to be a very first step for the pathogenesis of dengue. But till date, our knowledge is not that much about these receptor molecules in human monocytes, which are the prime targets of the dengue virus (DV). The envelop proteins from the virus and heparin sulfate of the host cell surface facilitates the binding between the virus and host cell through the receptors and play a key role in virus-cell attachment and binding. Controlling stretegies are also discussed with the vector control, chemical therapeutic antiviral agents and antiviral vaccines etc., along with brief introduction of neem based pesticide formulations developed at IPFT recently which are eco friendly and safe for humans as well.

References

  1. Kimura R. and Hotta S. (1944)., Studies on dengue fever (VI). On the inoculation of dengue virus into mice., Nippon Igazu, 3379, 629-633.
  2. Rigau-Pérez J.G., Clark G.G., Gubler D.J., Reiter P., Sanders E.J. and Vorndam A.V. (1998)., Dengue and dengue haemorrhagic fever., The Lancet, 352(9132), 971-977. http://dx.doi.org/10.1016/S0140-6736(97)12483-7
  3. Gubler D.J. (2002)., The global emergence/resurgence of arboviral diseases as public health problems., Archives of medical research, 33(4), 330-342.
  4. Halstead S.B. (2007)., Dengue., The lancet, 370(9599), 1644-1652.
  5. Gubler D.J., Suharyono W., Lubis I., Eram S. and Saroso J.S. (1979)., Epidemic denguehemorrhagic fever in rural Indonesia I. Virological and epidemiological studies., An. J. Trop. Med. Hyg., 59, 623-630.
  6. Gollins S.W. and Porterfield J.S. (1985)., Flavivirus infection enhancement in macrophages: an electron microscopic study of viral cellular entry., Journal of general virology, 66(9), 1969-1982.
  7. Gollins S.W. and Porterfield J.S. (1986)., A new mechanism for the neutralization of enveloped viruses by antiviral antibody., Nature, 321, 244-246.
  8. Peiris J.S.M. and Porterfield J.S. (1979)., Antibody-mediated enhancement of Flavivirus replication in macrophage-like cell lines., Nature, 282(5738), 509.
  9. Bielefeldt-Ohmann H., Meyer M., Fitzpatrick D.R. and Mackenzie J.S. (2001)., Dengue virus binding to human leukocyte cell lines: receptor usage differs between cell types and virus strains., Virus research, 73(1), 81-89.
  10. Hung Shang-Ling, Pei-Lun Lee, Hsiao-Wang Chen, Li-Kuang Chen, Chuan-Liang Kao and Chwan-Chuen King (1999)., Analysis of the steps involved in dengue virus entry into host cells., Virol., 257, 156-167.
  11. Chen Y., Maguire T., Hileman R.E., Fromm J.R., Esko J. D., Linhardt R.J. and Marks R.M. (1997)., Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate., Nature medicine, 3(8), 866-871.
  12. Gould A.P. and White R.A.H. (1992)., Connectin, a target of homeotic gene control in Drosophila., Development, 116(4), 1163-1174.
  13. Hernandez C., Maughan D.W. and Vigoreaux J.O. (1996)., Genetic and functional studies of flightin, a thick filament protein of Drosophila flight muscles., Mol. Biol. Cell, 7(Suppl.), 1161.
  14. Lu B., Ackerman L., Jan L.Y. and Jan Y.N. (1999)., Modes of protein movement that lead to the asymmetric localization of partner of Numb during Drosophila neuroblast division., Molecular cell, 4(6), 883-891.
  15. Germi R., Crance J.M., Garin D., Guimet J., Lortat-Jacob H., Ruigrok R.W. and Drouet E. (2002)., Heparan sulfate-mediated binding of infectious dengue virus type 2 and yellow fever virus., Virology, 292(1), 162-168.
  16. Kourí G., Guzmán M.G., Valdés L., Carbonel I., del Rosario D., Vázquez S. and Cabrera M.V. (1998)., Reemergence of dengue in Cuba: a 1997 epidemic in Santiago de Cuba., Emerging infectious diseases, 4(1), 89-92.
  17. Soper F.L. (1967)., Aedes aegypti and yellow fever., Bulletin of the World Health Organization, 36(4), 521-527.
  18. Bisset J.A., Rodríguez M.M., Ricardo Y., Ranson H., Perez O., Moya M. and Vazquez A. (2011)., Temephos resistance and esterase activity in the mosquito Aedes aegypti in Havana, Cuba increased dramatically between 2006 and 2008., Medical and Veterinary Entomology, 25(3), 233-239.
  19. Maciel-de-Freitas R., Aguiar R., Bruno R.V., Guimarães M. C., Lourenço-de-Oliveira R., Sorgine M.H. and Moreira L. A. (2012)., Why do we need alternative tools to control mosquito-borne diseases in Latin America?., Memórias do Instituto Oswaldo Cruz, 107(6), 828-829.
  20. Sá R.A., de Lima Santos N.D., da Silva C.S.B., Napoleão T.H., Gomes F.S., Cavada B.S. and Paiva P.M.G. (2009)., Larvicidal activity of lectins from Myracrodruon urundeuva on Aedes aegypti. Comparative Biochemistry and Physiology Part C., Toxicology & Pharmacology, 149(3), 300-306.
  21. Billingsley P.F., Foy B. and Rasgon J.L. (2008)., Mosquitocidal vaccines: a neglected addition to malaria and dengue control strategies., Trends in parasitology, 24(9), 396-400.
  22. Hanh T.T.T., Hill P.S., Kay B.H. and Quy T.M. (2009)., Development of a framework for evaluating the sustainability of community-based dengue control projects., The American journal of tropical medicine and hygiene, 80(2), 312-318.
  23. Halstead S.B. (1994)., 25 Antibody-dependent Enhancement of Infection: A Mechanism for Indirect Virus Entry into Cells., Cold Spring Harbor Monograph Archive, 28, 493-516.
  24. Sathyamangalam S., Gaurav B. and Navin K. (2010)., Dengue vaccines: state of the art., Expert Opinion on Therapeutic Patents, 20(6), 819-835.
  25. Gould E.A., Solomon T. and Mackenzie J.S. (2008)., Does antiviral therapy have a role in the control of Japanese encephalitis?., Antiviral research, 78(1), 140-149.
  26. Kinney R.M., Huang C.Y.H., Rose B.C., Kroeker A.D., Dreher T.W., Iversen P.L. and Stein D.A. (2005)., Inhibition of dengue virus serotypes 1 to 4 in vero cell cultures with morpholino oligomers., Journal of virology, 79(8), 5116-5128.
  27. Stein D.A., Huang C.Y.H., Silengo S., Amantana A., Crumley S., Blouch R.E. and Kinney R.M. (2008)., Treatment of AG129 mice with antisense morpholino oligomers increases survival time following challenge with dengue 2 virus., Journal of antimicrobial chemotherapy, 62(3), 555-565.
  28. Ray D. and Shi P.Y. (2006)., Recent advances in flavivirus antiviral drug discovery and vaccine development., Recent patents on anti-infective drug discovery, 1(1), 45-55.
  29. Shigeta S., Mori S., Kodama E., Kodama J., Takahashi K. and Yamase T. (2003)., Broad spectrum anti-RNA virus activities of titanium and vanadium substituted polyoxotungstates., Antiviral research, 58(3), 265-271.
  30. Leyssen P., Van Lommel A., Drosten C., Schmitz H., De Clercq E. and Neyts J. (2001)., A novel model for the study of the therapy of flavivirus infections using the Modoc virus., Virology, 279(1), 27-37.